SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Apellis Pharmaceuticals, Inc. (APLS) trades at a trailing P/E of 229.3, forward P/E of 33.8. Trailing earnings yield is 0.44%, forward earnings yield 2.96%. PEG 0.06 (Peter Lynch undervalued ≤1.0). Graham Number is $3.43.
Criteria proven by this page:
- VALUE (18/100, Fail) — trailing P/E is well above the S&P 500 average of ~25, suggesting a premium valuation (P/E 229.3); trailing earnings yield is below the 10-year Treasury yield (~4.3%), meaning bonds offer a better return (EY 0.44%); analyst consensus target implies downside from the current price ($33.50, 18%).
- Forward P/E 33.8 (down from trailing 229.3) — analysts expect earnings to grow, which would improve the valuation.
- PEG Ratio 0.06 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
- Trailing Earnings Yield 0.44% — below bond yields — investors are paying a premium for expected growth rather than current earnings. Forward yield improves to 2.96% as earnings recover.
- Analyst consensus target $33.50 (-18% downside) — analysts see meaningful downside risk at the current price level.
Overall SharesGrow Score: 48/100 with 1/7 criteria passed.
SharesGrow 7-Criteria Score
✗
VALUE
18/100
Price-to-Earnings & upside
Proven by this page
~
HEALTH
50/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — APLS
Valuation Multiples
P/E (TTM)229.3
Forward P/E33.8
PEG Ratio0.06
Forward PEG0.06
P/B Ratio13.87
P/S Ratio5.19
EV/EBITDA74.7
Per Share Data
EPS (TTM)$0.18
Forward EPS (Est.)$1.21
Book Value / Share$2.94
Revenue / Share$7.97
FCF / Share$0.36
Yields & Fair Value
Earnings Yield0.44%
Forward Earnings Yield2.96%
Dividend Yield0.00%
Graham Number$3.43
SharesGrow IV$37.40 (-8.4%)
Analyst Target$33.50 (-18%)
Historical Valuation
| Year |
P/E (TTM) |
PEG Ratio |
P/B Ratio |
P/S Ratio |
Dividend Yield |
| 2016 |
-9.4 |
0.22 |
10.67 |
0.00 |
- |
| 2017 |
-14.6 |
21.84 |
4.99 |
0.00 |
- |
| 2018 |
-5.6 |
-0.10 |
4.46 |
0.00 |
- |
| 2019 |
-6.3 |
-0.06 |
55.67 |
0.00 |
- |
| 2020 |
-12.5 |
1.59 |
21.02 |
17.15 |
- |
| 2021 |
-5.3 |
-0.06 |
20.09 |
59.96 |
- |
| 2022 |
-8.4 |
0.28 |
32.30 |
72.75 |
- |
| 2023 |
-13.4 |
0.49 |
36.52 |
17.91 |
- |
| 2024 |
-20.0 |
0.31 |
17.30 |
5.06 |
- |
| 2025 |
141.4 |
-1.27 |
8.55 |
3.15 |
- |
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$-1.50 |
$0.00 |
$-27.13M |
- |
| 2017 |
$-3.68 |
$0.00 |
$-51.01M |
- |
| 2018 |
$-2.34 |
$0.00 |
$-127.5M |
- |
| 2019 |
$-4.98 |
$0.00 |
$-309.82M |
- |
| 2020 |
$-4.59 |
$250.65M |
$-344.87M |
-137.6% |
| 2021 |
$-8.84 |
$66.56M |
$-746.35M |
-1121.3% |
| 2022 |
$-6.15 |
$75.42M |
$-652.17M |
-864.7% |
| 2023 |
$-4.45 |
$396.59M |
$-528.63M |
-133.3% |
| 2024 |
$-1.60 |
$781.37M |
$-197.88M |
-25.3% |
| 2025 |
$0.18 |
$1B |
$22.39M |
2.2% |
Analyst Estimates
| Year |
EPS (Avg) |
EPS Range |
Revenue (Avg) |
Revenue Range |
Analysts |
| 2026 |
$-1.12 |
$-1.95 – $-0.68 |
$861.54M |
$813.33M – $928.62M |
15 |
| 2027 |
$-0.20 |
$-0.76 – $0.11 |
$1.02B |
$893.21M – $1.16B |
14 |
| 2028 |
$1.18 |
$-0.92 – $7.82 |
$1.26B |
$1.26B – $1.26B |
17 |
| 2029 |
$1.50 |
$1.30 – $1.73 |
$1.37B |
$1.22B – $1.53B |
13 |
| 2030 |
$2.48 |
$2.14 – $2.86 |
$1.54B |
$1.37B – $1.72B |
7 |
